EVP-6124

DRUG9 trials

Sponsors

FORUM Pharmaceuticals Inc, A. Eden Evins

Conditions

Alzheimer's DiseaseCardiac RepolarizationCentral Nervous System DiseasesCognitionDementiaHealthy SubjectsImpaired CognitionNicotine Dependence

Phase 1

Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects

CompletedNCT01487135

FORUM Pharmaceuticals IncCardiac Repolarization, Healthy Subjects

Start: 2011-12-31End: 2013-09-30Updated: 2014-10-10

Phase 2

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

CompletedNCT00968851

FORUM Pharmaceuticals IncCentral Nervous System Diseases, Cognition, Schizophrenia

Start: 2009-12-31End: 2011-03-31Updated: 2014-04-25

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

CompletedNCT01073228

FORUM Pharmaceuticals IncAlzheimer's Disease, Central Nervous System Diseases, Cognition

Start: 2010-04-30End: 2012-02-29Updated: 2014-04-25

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

TerminatedNCT01480232

A. Eden EvinsNicotine Dependence, Smoking Cessation

Start: 2011-12-31End: 2015-09-30Updated: 2017-04-06

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

WithdrawnNCT02246075

FORUM Pharmaceuticals IncAlzheimer's Disease, Cognition, Dementia

Start: 2015-07-31Updated: 2015-10-15

Phase 3

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

CompletedNCT01714713

FORUM Pharmaceuticals IncImpaired Cognition, Schizophrenia

Start: 2013-06-30End: 2015-10-31Updated: 2016-05-03

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

CompletedNCT01714661

FORUM Pharmaceuticals IncImpaired Cognition, Schizophrenia

Start: 2012-10-31End: 2015-12-31Updated: 2016-05-03

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

CompletedNCT01716975

FORUM Pharmaceuticals IncImpaired Cognition, Schizophrenia

Start: 2012-10-31End: 2016-02-29Updated: 2016-05-03

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

TerminatedNCT02004392

FORUM Pharmaceuticals IncAlzheimer's Disease, Dementia

Start: 2014-06-30End: 2017-08-31Updated: 2016-05-03